Clinical trial · Interventional
Letrozole Alone Protocol Versus Using Letrozole and HCG Protocol
The Effect of Using Letrozole Alone Protocol Versus Using Letrozole and HCG Protocol on Induction of Ovulation in Polycystic Ovarian Syndrome Patients: A Prospective Cohort Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Letrozole is a chemical compound, CGS 20267 which is a third-generation, nonsteroidal aromatase inhibitor. Letrozole blocks estrogen synthesis by directly affecting the hypothalamic-pituitary-ovarian axis, subsequently, increases gonadotropins which increase pregnancy rates. Possible positive outcomes of aromatase inhibitors over selective estrogen-receptor modulators include a more physiologic hormonal stimulation of the endometrium which increases receptivity, a lower multiple-pregnancy through single follicle growth, a lesser side-effect especially vasomotor and mood symptoms, and more prompt clearance from blood, hence, reducing the probabilities of periconceptional exposure
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Letrozole tablets | Drug | Letrozole | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Group A: letrozole only
- description
- About 66 Patients took Letrozole drug only for induction of ovulation at the time of suspected ovulation maturity.
- interventionNames
- Drug: Letrozole tablets
- type
- ACTIVE_COMPARATOR
- label
- Group B: letrozole + HCG
- description
- About 66 Patients took Letrozole drug in addition to HCG for induction of ovulation at the time of suspected ovulation maturity.
- interventionNames
- Drug: Letrozole tablets
Primary outcomes (1)
- measure
- Pregnancy test
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 35 Years
Show eligibility criteria text
Inclusion Criteria: * Infertile women with PCOS * Normal hysterosalpingography * Normal semen analysis according to WHO parameters are major prerequisites Exclusion Criteria: * Infertile women with causes other than PCOS, * Ages \<18 or \>35 years * women taken confounding medications like other infertility drugs * Insulin sensitizers or hormones * Abnormal hysterosalpingography * Subnormal semen analysis
References
Publications (0)
Data not yet available